These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27338043)

  • 21. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
    Chen F; Luo N; Hu Y; Li X; Zhang K
    Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CircRNA_0044556 affects the sensitivity of triple-negative breast cancer cells to paclitaxel by regulating miR-665.
    Chen JJ; Shi P; Cui ZC; Jiang N; Ma J
    J Chemother; 2024 Jun; ():1-9. PubMed ID: 38850033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells.
    Tao J; Wu D; Li P; Xu B; Lu Q; Zhang W
    Mol Med Rep; 2012 Jan; 5(1):167-72. PubMed ID: 21935572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
    Rasoolnezhad M; Safaralizadeh R; Hosseinpour Feizi MA; Banan-Khojasteh SM; Roshani Asl E; Lotfinejad P; Baradaran B
    Mol Biol Rep; 2023 Oct; 50(10):8407-8420. PubMed ID: 37620737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest.
    Wang Y; Wu N; Zhang J; Wang H; Men X
    Onco Targets Ther; 2020; 13():4089-4097. PubMed ID: 32494162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-182 targets FOXF2 to promote the development of triple-negative breast cancer.
    Yu J; Shen W; Gao B; Zhao H; Xu J; Gong B
    Neoplasma; 2017; 64(2):209-215. PubMed ID: 28043147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
    Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
    Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
    Yi M; Peng C; Xia B; Gan L
    Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer.
    Zheng M; Wu Z; Wu A; Huang Z; He N; Xie X
    Tumour Biol; 2016 Jul; 37(7):8599-607. PubMed ID: 26733177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-200c/PAI-2 promotes the progression of triple negative breast cancer via M1/M2 polarization induction of macrophage.
    Meng Z; Zhang R; Wang Y; Zhu G; Jin T; Li C; Zhang S
    Int Immunopharmacol; 2020 Apr; 81():106028. PubMed ID: 31801690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1.
    Zhu HY; Bai WD; Ye XM; Yang AG; Jia LT
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1308-1313. PubMed ID: 29408336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
    Xue J; Chi Y; Chen Y; Huang S; Ye X; Niu J; Wang W; Pfeffer LM; Shao ZM; Wu ZH; Wu J
    Oncogene; 2016 Jan; 35(4):448-58. PubMed ID: 25867061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
    Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
    Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
    Wang J; Ye C; Liu J; Hu Y
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.